 As of 2014 there was insufficient evidence to show that eculizumab therapy improves life expectancy for people with paroxysmal nocturnal hemoglobinuria, and the cost-effectiveness was poor.In 2010 Alexion priced Soliris as the most expensive drug in the world, at approximately US$409,500 a year in the United States (2010), €430,000 per year for ongoing treatment in the UK, and $500,000 a year in Canada (2014).Alexion started selling Soliris in 2008, making $295 million in 2007 with its stock price rising to 130% in 2010.